MENU
+Compare
OGN
Stock ticker: NYSE
AS OF
Sep 5, 04:59 PM (EDT)
Price
$10.39
Change
+$0.71 (+7.33%)
Capitalization
2.52B

OGN stock forecast, quote, news & analysis

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands... Show more

OGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. OGN showed earnings on August 05, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for OGN with price predictions
Sep 04, 2025

OGN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for OGN turned positive on August 15, 2025. Looking at past instances where OGN's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OGN's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on OGN as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

OGN moved above its 50-day moving average on September 03, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for OGN crossed bearishly below the 50-day moving average on August 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OGN broke above its upper Bollinger Band on September 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.433) is normal, around the industry mean (9.469). OGN has a moderately low P/E Ratio (3.599) as compared to the industry average of (23.988). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.777). OGN's Dividend Yield (0.062) is considerably higher than the industry average of (0.028). OGN's P/S Ratio (0.401) is slightly lower than the industry average of (3.455).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

A.I.Advisor
published Dividends

OGN is expected to pay dividends on September 11, 2025

Organon & Co OGN Stock Dividends
A dividend of $0.02 per share will be paid with a record date of September 11, 2025, and an ex-dividend date of August 15, 2025. The last dividend of $0.02 was paid on June 12. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 90.72B. The market cap for tickers in the group ranges from 72.83K to 665.99B. LLY holds the highest valuation in this group at 665.99B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 10%. CSPCY experienced the highest price growth at 17%, while PTKFF experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was -45% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 70
Price Growth Rating: 54
SMR Rating: 61
Profit Risk Rating: 79
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
OGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
30 Hudson Street
Phone
+1 551 430-6900
Employees
10000
Web
https://www.organon.com